Nomura Holdings’s Mineralys Therapeutics MLYS Stock Holding History

Nomura Holdings’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$542K	–	1958
2026 Q1	$542K	Buy	+20,000	New	+$587K	﹤0.01%	1339

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nomura Holdings's MLYS Position: Q2 2026 in Review

Nomura Holdings sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 20,000 shares — an estimated $542K sold.

Nomura Holdings first reported a position in MLYS in Q1 2026 and held it in 1 quarter. The position peaked at $542K in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Nomura Holdings reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
Nomura Holdings sold 20,000 Mineralys Therapeutics shares in Q2 2026, an estimated $542K.
Nomura Holdings first reported a position in Mineralys Therapeutics in Q1 2026 and held it in 1 quarter.
Nomura Holdings's Mineralys Therapeutics position peaked at $542K in Q1 2026.
226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.